Issue 4/2023
Content (10 Articles)
Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells
- Open Access
- Breast Cancer
- Research
Minhong Tang, John Crown, Michael J Duffy
A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma
- Melanoma
- Research
Elizabeth I. Buchbinder, Anita Giobbie-Hurder, Rizwan Haq, Patrick A. Ott
POTEE mutation as a potential predictive biomarker for immune checkpoint inhibitors in lung adenocarcinoma
- NSCLC
- Research
Yongzhao Li, Qidong Yang, Yaqin Liu, Huan Yi, Yongzhi Ju, Guoyan Qi
Sitravatinib is a potential EGFR inhibitor and induce a new death phenotype in Glioblastoma
- Glioblastoma
- Research
Hanwen Lu, Bingchang Zhang, Yuanyuan Xie, Wenpeng Zhao, Wanhong Han, Liwei Zhou, Zhanxiang Wang
Safety and efficacy of immunotherapy plus chemotherapy as neoadjuvant treatment for patients with locally advanced gastric cancer: a retrospective cohort study
- Gastric Cancer
- Research
Xue Wang, Jinxiang Huang, He Huang, Yang Liu, Chao Ji, Jian Liu
The p53 reactivator PRIMA-1MET synergises with 5-fluorouracil to induce apoptosis in pancreatic cancer cells
- Pancreatic Cancer
- Research
Ibtehal Mohammed, Ali Haider Alhammer, Inam Sameh Arif
Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates
- Open Access
- Dabigatran
- Research
Özkan Yalkinoglu, Andreas Becker, Axel Krebs-Brown, Claudia Vetter, Christian Lüpfert, Dominique Perrin, Jürgen Heuer, Herlind Biedert, Stefan Hirt, Afrim Bytyqi, Angelika Bachmann, Rainer Strotmann
Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma
- Open Access
- Zanubrutinib
- Research
Yuqin Song, Keshu Zhou, Shenmiao Yang, Jianda Hu, Dehui Zou, Sujun Gao, Ling Pan, Tingyu Wang, Haiyan Yang, Huilai Zhang, Daobin Zhou, Jie Ji, Wei Xu, Ru Feng, Jie Jin, Fangfang Lv, Haiwen Huang, Xiaosi Fan, Sheng Xu, Jun Zhu
Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study
- Hepatocellular Carcinoma
- Research
Chenghao Zhao, Huzheng Yan, Zhanwang Xiang, Haofan Wang, Mingan Li, Mingsheng Huang
Correction to: The kinesin motor protein KIF4A as a potential therapeutic target in renal cell carcinoma
- Kidney Cancer
- Correction
Guihong Liu, Yachun Lu, Liantao Li, Tao Jiang, Sufang Chu, Pingfu Hou, Jin Bai, Ming Chen
